FI942884L - Menetelmiä osteoporoosin hoitamiseksi käyttäen bisfosfonaatteja ja paratyreoideahormonia - Google Patents

Menetelmiä osteoporoosin hoitamiseksi käyttäen bisfosfonaatteja ja paratyreoideahormonia Download PDF

Info

Publication number
FI942884L
FI942884L FI942884A FI942884A FI942884L FI 942884 L FI942884 L FI 942884L FI 942884 A FI942884 A FI 942884A FI 942884 A FI942884 A FI 942884A FI 942884 L FI942884 L FI 942884L
Authority
FI
Finland
Prior art keywords
bisphosphonates
methods
parathyroid hormone
treating osteoporosis
osteoporosis
Prior art date
Application number
FI942884A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI942884A0 (fi
FI942884A7 (fi
Inventor
Ann Dunbar Geddes
Rogely Waite Boyce
Original Assignee
Procter & Gamble Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble Pharma filed Critical Procter & Gamble Pharma
Publication of FI942884A0 publication Critical patent/FI942884A0/fi
Publication of FI942884A7 publication Critical patent/FI942884A7/fi
Publication of FI942884L publication Critical patent/FI942884L/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI942884A 1991-12-17 1992-12-15 Menetelmiä osteoporoosin hoitamiseksi käyttäen bisfosfonaatteja ja paratyreoideahormonia FI942884L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80962091A 1991-12-17 1991-12-17
PCT/US1992/010869 WO1993011786A1 (fr) 1991-12-17 1992-12-15 Methodes de traitement de l'osteoporose faisant appel a des bisphosphonates et a une hormone parathyroidienne

Publications (3)

Publication Number Publication Date
FI942884A0 FI942884A0 (fi) 1994-06-16
FI942884A7 FI942884A7 (fi) 1994-06-16
FI942884L true FI942884L (fi) 1994-06-16

Family

ID=25201804

Family Applications (1)

Application Number Title Priority Date Filing Date
FI942884A FI942884L (fi) 1991-12-17 1992-12-15 Menetelmiä osteoporoosin hoitamiseksi käyttäen bisfosfonaatteja ja paratyreoideahormonia

Country Status (18)

Country Link
US (1) US5616560A (fr)
EP (1) EP0618805A1 (fr)
JP (1) JPH07502507A (fr)
AU (2) AU3322593A (fr)
BR (1) BR9206941A (fr)
CA (1) CA2124792C (fr)
CZ (1) CZ282889B6 (fr)
FI (1) FI942884L (fr)
HU (1) HUT68010A (fr)
IL (1) IL104108A (fr)
MA (1) MA23079A1 (fr)
MX (1) MX9207349A (fr)
NO (1) NO942241D0 (fr)
NZ (1) NZ246456A (fr)
RU (2) RU2112515C1 (fr)
SK (1) SK74594A3 (fr)
WO (1) WO1993011786A1 (fr)
ZA (1) ZA929758B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2124792C (fr) * 1991-12-17 2000-07-04 Ann D. Geddes Methodes de traitement de l'osteoporose par les biphosphonates et l'hormone parathyroidienne
AU4859493A (en) * 1992-10-09 1994-05-09 Upjohn Company, The Pyrimidine bisphosphonate esters and (alkoxymethylphosphinyl)alkyl phosphonic acids as anti-inflammatories
FR2703590B1 (fr) 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
US6013792A (en) * 1993-08-05 2000-01-11 Syntex (U.S.A.), Inc. Matrix metalloprotease inhibitors
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
CA2199251A1 (fr) * 1994-09-09 1996-03-14 Ann Dunbar Geddes Phosphonates et parathormone contre l'osteoporose
WO1996007417A1 (fr) * 1994-09-09 1996-03-14 The Procter & Gamble Company Procedes de traitement de l'osteoporose utilisant des phosphonates osteoactifs et une hormone parathiroïdienne
WO1996019246A1 (fr) * 1994-12-19 1996-06-27 Beth Israel Hospital Association Administration en continu de faibles doses d'hormone parathyroïdienne ou de son agoniste
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
CA2208714C (fr) * 1994-12-28 2003-10-21 Gador S.A. Composition a action anabolique sur la masse osseuse contenant de l'olpadronate
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
EP0891779A1 (fr) * 1997-06-19 1999-01-20 Roche Diagnostics GmbH Compositions pharmaceutiques contenant l'hormone parathyrodienne et du calcium et/ou des composés phosphorés
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
EP0922467A3 (fr) * 1997-12-12 2000-05-24 Takeda Chemical Industries, Ltd. Administration de médicaments par ionophorèse
RU2155588C2 (ru) * 1998-10-16 2000-09-10 Общество с ограниченной ответственностью "Институт фармацевтических реактивов РЕФАРМ" Способ увеличения массы костной ткани при переломах
US6495662B1 (en) * 1998-10-22 2002-12-17 The General Hospital Corporation Bioactive peptides and peptide derivatives of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP)
WO2000032771A1 (fr) 1998-11-30 2000-06-08 The General Hospital Corporation Recepteurs de pth1r et de pth3r, procedes s'y rapportant et utilisation
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
AU7734800A (en) * 1999-09-29 2001-04-30 General Hospital Corporation, The Polypeptide derivatives of parathyroid hormone (pth)
HU228400B1 (en) 2000-06-20 2013-03-28 Novartis Ag The use of bisphosphonates for treatment of osteoporosis
CA2372450A1 (fr) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Preparation injectable liquide de pamidronate disodique
KR100491737B1 (ko) * 2001-07-20 2005-05-27 주식회사 한국아이템개발 공기 정화 기능의 모기 퇴치기
AU2002339843B2 (en) 2001-07-23 2007-12-06 The General Hospital Corporation Conformationally constrained parathyroid hormone (PTH) analogs
WO2003015822A1 (fr) * 2001-08-17 2003-02-27 Novartis Ag 5-cnac utilise en tant qu'agent d'administration par voie orale pour des fragments d'hormone parathyroidienne
US20050176685A1 (en) * 2002-04-05 2005-08-11 Daifotis Anastasia G. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
CN1939314A (zh) * 2002-05-10 2007-04-04 弗·哈夫曼-拉罗切有限公司 用于治疗和预防骨质疏松症的二膦酸
RU2219933C1 (ru) * 2002-07-22 2003-12-27 Волова Лариса Теодоровна Способ стимуляции остеогенеза
US20040097468A1 (en) * 2002-11-20 2004-05-20 Wimalawansa Sunil J. Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
EP1610813A4 (fr) * 2003-03-19 2009-07-01 Gen Hospital Corp Hormones parathyroidiennes contraintes de maniere conformationnelle avec des stabilisateurs en helice $g(a)
JP5229768B2 (ja) * 2003-06-26 2013-07-03 シヴィダ・ユーエス・インコーポレイテッド Ｉｎ−Ｓｉｔｕゲル化薬物輸送システム
JP4871128B2 (ja) 2003-07-17 2012-02-08 ザ ジェネラル ホスピタル コーポレイション 高次構造的に制約された副甲状腺ホルモン（ｐｔｈ）アナログ
EP1651246A4 (fr) * 2003-08-06 2009-06-24 Innophos Inc Procede pour favoriser la croissance osseuse
US20050043359A1 (en) * 2003-08-20 2005-02-24 The Procter & Gamble Company Kit for treatment of upper gastrointestinal tract conditions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
RU2273493C1 (ru) * 2004-10-15 2006-04-10 Валерий Николаевич Зеленков Композиция для профилактики и лечения болезней, вызываемых дефицитом кальция (варианты)
CN101355959B (zh) * 2005-11-10 2013-02-27 密歇根理工大学管理委员会 黑熊甲状旁腺素和使用黑熊甲状旁腺素的方法
US8143374B2 (en) * 2006-08-04 2012-03-27 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (PTH)
AU2008252853B2 (en) * 2007-05-24 2011-12-01 Ablynx N.V. Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders
MX353986B (es) 2007-08-01 2017-11-06 Massachusetts Gen Hospital Metodos de analisis y seleccion usando receptores acoplados a proteina g y composiciones relacionadas.
CA2782640A1 (fr) 2009-12-07 2011-06-16 Michigan Technological University Hormone parathyroide de l'ours noir et ses procedes d'utilisation
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
JP5941040B2 (ja) 2010-05-13 2016-06-29 ザ ジェネラル ホスピタル コーポレイション 副甲状腺ホルモン類似体およびその使用
WO2016163886A2 (fr) 2015-04-10 2016-10-13 Clues2Cure International B.V. Administration de taurine ou d'un analogue de celle-ci pour le traitement de lésions de cellules nerveuses
WO2020090174A1 (fr) 2018-10-29 2020-05-07 旭化成ファーマ株式会社 Méthode de prévention ou de traitement de l'ostéoporose caractérisée par l'administration de tériparatide ou d'un sel de celui-ci deux fois par semaine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) * 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
DE3243358A1 (de) * 1982-11-24 1984-05-24 Rolf Dieter Prof.Dr. 3004 Isernhagen Hesch Synthetisches humanes (1-38) parathormon-fragment, verfahren zu seiner herstellung und die verwendung zur behandlung der osteoporose
US4812304A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
US4822609A (en) * 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
US4812311A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
CA2124792C (fr) * 1991-12-17 2000-07-04 Ann D. Geddes Methodes de traitement de l'osteoporose par les biphosphonates et l'hormone parathyroidienne

Also Published As

Publication number Publication date
RU2104699C1 (ru) 1998-02-20
NO942241L (fr) 1994-08-09
RU2112515C1 (ru) 1998-06-10
CA2124792C (fr) 2000-07-04
NZ246456A (en) 1997-03-24
AU3322593A (en) 1993-07-19
NO942241D0 (no) 1994-06-15
HU9401798D0 (en) 1994-09-28
FI942884A0 (fi) 1994-06-16
SK74594A3 (en) 1995-01-12
CZ282889B6 (cs) 1997-11-12
EP0618805A1 (fr) 1994-10-12
RU94031209A (ru) 1996-07-27
HUT68010A (en) 1995-05-29
ZA929758B (en) 1993-09-10
JPH07502507A (ja) 1995-03-16
FI942884A7 (fi) 1994-06-16
US5616560A (en) 1997-04-01
AU3022692A (en) 1993-06-24
WO1993011786A1 (fr) 1993-06-24
IL104108A0 (en) 1993-05-13
MA23079A1 (fr) 1993-07-01
CZ147794A3 (en) 1994-12-15
MX9207349A (es) 1993-12-01
BR9206941A (pt) 1995-05-02
CA2124792A1 (fr) 1993-06-24
AU663348B2 (en) 1995-10-05
IL104108A (en) 1999-09-22

Similar Documents

Publication Publication Date Title
FI942884A0 (fi) Menetelmiä osteoporoosin hoitamiseksi käyttäen bisfosfonaatteja ja paratyreoideahormonia
FI922356L (fi) Vaesentligen rent humant paratyroidhormon
FI950171A7 (fi) Paratyreoideahormonin (PTH) analogit
ZA925391B (en) Trifluoromethylbenzylphosphonates useful in treating osteoporosis
DE69221636D1 (de) Vorrichtung zum Mischen von Knochenzement
FI953926L (fi) Hormonin palautushoito
FI941133L (fi) Koostumus ja menetelmä hepatiitti C:n hoitamiseksi
FI893847A7 (fi) Menetelmä päivämäärän ja kellonajan korjaamiseksi
ZA914556B (en) Intramedullary nailing method and apparatus
EP0502460A3 (en) System for treating contaminated groundwater
DE69311431D1 (de) Vorrichtung zum externen Festlegen von Knochen
DE69117788D1 (de) Parathyroid-Hormon-Antagonisten
DE69230912D1 (de) Radioaktiv-markiertes metall-bindendes protein zur behandlung von arthritis
LT99010A (en) Parathyroid hormone analogues for the treatment of osteoporosis
FI953967A0 (fi) Laite ja menetelmä jauheen kostuttamiseksi
FI990126A7 (fi) Paratyreoideahormonianalogeja osteoporoosin hoitoon
DE69527140D1 (de) Wirkstoff zur prävention oder behandlung von osteoporose
IL104940A0 (en) Method and composition for the treatment of osteoporosis
GR910100192A (en) Method for preparing a composition for the osteoporosis and hormone imbalance treatment
GB8905714D0 (en) Osteoporosis treatment
FI911268A7 (fi) Menetelmä ja koostumus iontoforeesia varten
EP0779813A4 (fr) Phosphonates et parathormone contre l'osteoporose
FI924223A7 (fi) Menetelmä ja laite puhdistussäätöön
EP0804202A4 (fr) Oestrogenes et hormone parathyroidienne utiles pour traiter l'osteoporose
FI905564A0 (fi) Menetelmä ja laite alkulevyn irrottamiseksi